Results 131 to 140 of about 98,067 (307)
Improved survival with fludarabine‐based therapies in mixed phenotype acute leukaemia: A population‐based study using the WHO 2022 classification
British Journal of Haematology, EarlyView.Summary
Mixed phenotype acute leukaemia (MPAL) is a rare subtype of acute leukaemia possessing significant therapeutic challenges, as no standardized, evidence‐based treatment regimen has been defined. In this nationwide study, we aimed to assess the effect of an acute lymphoid leukaemia (ALL)‐like regimen; an acute myeloid leukaemia (AML)‐like regimen;Lisa‐Maj Christensen, Mikkel Runason Simonsen, Jonas Faartoft Jensen, Daniel Tuyet Kristensen, Karen Dybkær, Kirsten Grønbæk, Tarec Christoffer El‐Galaly, Marianne Schmidt Ettrup, Hans Beier Ommen, Anne Louise Tølbøll Sørensen, Dennis Lund Hansen, Marianne Tang Severinsen +11 morewiley +1 more sourceHigh frequency of CD95+/CD45RA− regulatory T cells defines an immunosuppressive profile associated with MDS progression
British Journal of Haematology, EarlyView.Summary
Dynamic interactions between mutated haematopoietic cells and immune cells are key drivers of myelodysplastic neoplasms (MDS) initiation and progression. Regulatory T cells (Tregs) are central mediators of immunosuppression in MDS. We thus aimed to characterize Treg subpopulations in the bone marrow (BM) of MDS patients and to explore their ...Romain Vazquez, Nicolas Deredec, Ismael Boussaid, Pierre Boncoeur, Camille Knosp, Amandine Houvert, Loria Zalmai, Chloe Friedrich, Carole Almire, Charles Dussiau, Lise Willems, Rudy Birsen, Justine Decroocq, Didier Bouscary, Olivier Kosmider, Shahram Kordasti, Michaela Fontenay, Yannick Simoni, Nicolas Chapuis +18 morewiley +1 more sourceO55: Evaluation of a large cohort of spontaneous pregnancy losses: Intriguing findings from both chromosome and microarray studies
Genetics in Medicine OpenStuart Schwartz, Alexandra Arreola, Inder Gadi, Gloria Haskell, Bing Huang, Judith Knops, Zach Ou, Andrea Penton, Karen Phillips, Amanda Sussman, James Tepperberg +10 moredoaj +1 more sourceDay‐30 IL1RL1, CXCL9 and REG3α are prognostic for survival after mismatched unrelated donor transplantation
British Journal of Haematology, EarlyView.Summary
While plasma‐derived proteins have emerged as potential biomarkers for prognosis after haematopoietic stem cell transplantation (HSCT), there are insufficient data assessing if established proteins interleukin 1 receptor‐like 1 (IL1RL1), chemokine ligand 9 (CXCL9) and regenerating islet‐derived 3‐α (REG3α) retain their utility in the mismatched Trent Wang, Anna C. Ferreira, Nasheed M. Hossain, Denggang Fu, Elizabeth G. Hill, Antonio M. Jimenez Jimenez, Cara Benjamin, Krishna V. Komanduri, Sophie Paczesny +8 morewiley +1 more sourceReal‐world treatment patterns and outcomes in accelerated and blast‐phase myeloproliferative neoplasms: Insights from a large multi‐centre cohort analysis in the United Kingdom
British Journal of Haematology, EarlyView.Summary
This UK‐based retrospective analysis describes real‐world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast‐phase (BP, n = 106) ‘Philadelphia‐negative’ myeloproliferative neoplasms (MPN‐AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years.Alexandros Rampotas, Gabriel Naylor‐Layland, Clare Brown, Ahmad Alabdulkarim, Jennifer Ryan, Frances Wadelin, Samah Alimam, Phyo Wint Wint Tun, Jonathan Lambert, Jennifer O'Sullivan, Andrew J. Wilson, Laith Tafesh, Andrew McGregor, Simone Claudiani, Andrew Innes, Emily Booth, James Leveson, Steve Knapper, Mamta Garg, Mani Dubey, Theodora Vatopoulou, Charlotte Brierley, Wai Ka Natalie Leung, Graham Greenfield, Mary Frances McMullin, Alesia Khan, Kate Milne, Duncan Brian, Anna Godfrey, Claire N. Harrison, Bethan Psaila, Patrick Harrington, Amy Kirkwood, Tim C. P. Somervaille, Donal P. McLornan, on behalf of the UK Blood Cancer Research Network MPN Clinical Study Group +35 morewiley +1 more sourcecytogenetics
Citation: 'cytogenetics' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.10583 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.openaire +1 more sourceMolecular and clinical features of a Japanese medulloblastoma cohort: Subgroup‐specific prognostic stratification using economical/accessible diagnostic methods
Brain Pathology, EarlyView.This study characterizes the molecular subgroup–specific features of a nationwide Japanese cohort comprising 242 medulloblastomas (MBs). Furthermore, we introduce SEE‐6‐CNA, a simple, cost‐effective, and FFPE‐compatible molecular test that is applicable to routine pathology samples and serves as a surrogate for risk stratification in non‐WNT/non‐SHH ...Kohichi Go, Asako Katsuma, Ema Yoshioka, Tomoko Shofuda, Kohei Fukuoka, Koichi Ichimura, Yuko Matsushita, Yohei Mineharu, Yasuhide Makino, Takeshi Kawauchi, Atsushi Sasaki, Junko Hirato, Takeshi Inoue, Yoshinori Kodama, Masayuki Mano, Daisuke Kanematsu, Noriyuki Kijima, Naoki Kagawa, Dai Keino, Akitake Mukasa, Tomonari Suzuki, Koji Yoshimoto, Daisuke Kuga, Keishi Horiguchi, Shigeru Yamaguchi, Masayuki Kanamori, Kai Yamasaki, Kenichi Ishibashi, Takuya Akai, Masayoshi Yamaoka, Ryuji Ishizaki, Atsufumi Kawamura, Shigeo Ohba, Joji Ishida, Ryo Ando, Junya Fukai, Tomoru Miwa, Masazumi Fujii, Ai Muroi, Kuniaki Saito, Atsuko Harada, Yasuhiko Hayashi, Masahiro Nonaka, Young‐Soo Park, Yusuke Kobayashi, Tadashi Higuchi, Yosuke Miyairi, Kazuhisa Yoshifuji, Noriyoshi Takebe, Soichi Oya, Kosuke Nakajo, Mitsutoshi Nakada, Yoshiteru Nakano, Mizuki Kambara, Koji Adachi, Kazuhiro Tanaka, Hideo Nakamura, Yukihiko Sonoda, Ryuta Saito, Takafumi Wataya, Kazuhiko Kurozumi, Michael D. Taylor, Yoshitaka Narita, Soichiro Shibui, Hajime Arai, Hiroaki Sakamoto, Isao Date, Motoo Nagane, Ryo Nishikawa, Yoshiki Arakawa, Yonehiro Kanemura +70 morewiley +1 more sourceEnhancing antitumour response to proteasome inhibitors with inhibitors of insulin‐degrading enzyme, a new molecular vulnerability in multiple myeloma
British Journal of Pharmacology, EarlyView.Inhibitors of insulin‐degrading enzyme boost PI cytotoxicity through an increased sensitivity of proteasome to PI inhibitors, induction of ISR, DNA damage and Myc down‐regulation. They overcome PI resistance in vitro and induce tumour regression in vivo.Laetitia Lesire, Rebecca Deprez‐Poulain, Damien Bosc, Florence Leroux, Valerie Landry, Sarah Ourabah, Morgane Tardy, Clara Maillard, Ronan Gealageas, Julie Dumont, Adrien Herledan, Sandrine Warenghem, Manon Cruette, Celine Lenglart, Alexandre Biela, Catherine Piveteau, Eva De Smedt, Catharina Muylaert, Wenguang Liang, Elvira Garcia De Paco, Elina Alaterre, Sara Ovejero, Nicolas Robert, Fabien Delahaye, Wei‐Jen Tang, Peter van Endert, Elke De Bruyne, Jérôme Moreaux, Benoit Deprez +28 morewiley +1 more source
